Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?
AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.
Pharma & Biotech
Pharma & Biotech
Can Lynx Analytics’ Lumen framework reshape AI-driven decision-making in life sciences?
Lynx Analytics has introduced Lumen, a dedicated agentic artificial intelligence framework designed to support complex decision-making across life sciences workflows. The launch was anchored by a real-world deployment at AstraZeneca, where a custom-built application called IlluminAI is now embedded in the oncology team’s brand planning process across international markets. The framework is positioned as a
Medical Devices & Diagnostics
GT Medical Technologies’ BRIDGES trial begins enrollment, testing GammaTile in newly diagnosed glioblastoma patients
GT Medical Technologies has announced the first patient enrollments in its BRIDGES trial, a randomized clinical study assessing the use of GammaTile therapy in newly diagnosed glioblastoma. The trial introduces GammaTile at the time of initial tumor resection, marking a notable shift from the conventional glioblastoma radiation timeline, which typically delays radiation until several weeks
Medical Devices & Diagnostics
Robotic cochlear implants approved for kids: Is iotaSOFT reshaping pediatric ENT standards?
iotaMotion, Inc. has received U.S. Food and Drug Administration 510(k) clearance to expand the approved use of its iotaSOFT Robotic-Assisted Cochlear Implant Insertion System for children as young as four years old. This regulatory milestone makes the iotaSOFT system the first robotic-assisted cochlear insertion platform authorized for use in school-aged pediatric patients, expanding access to
Pharma & Biotech
Cereno Scientific’s CS014 shows antithrombotic effect without bleeding risk in new HDAC study
Cereno Scientific has announced the peer-reviewed publication of its next-generation HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, revealing the compound’s ability to significantly reduce thrombosis without increasing bleeding risk. The study marks the first formal disclosure of CS014’s chemical structure and nonclinical pharmacology, positioning the compound as a differentiated HDAC inhibitor with
Medical Devices & Diagnostics
Vista AI raises $29.5m to expand automated MRI scanning beyond cardiology
Vista AI, a U.S.-based medical imaging software company specializing in AI-powered MRI automation, has raised $29.5 million in Series B financing to accelerate its product roadmap and scale adoption across U.S. hospitals and imaging centers. The funding round, announced on January 14, 2026, includes strategic investments from leading health systems such as Cedars-Sinai Health System,
Pharma & Biotech
How annamycin’s clean cardiac safety profile may strengthen Moleculin’s oncology development strategy
Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this safety milestone may reshape its oncology development path.
Pharma & Biotech
Why Creative Medical Technology Holdings’ ADAPT interim results may mark a turning point for cell-based chronic pain treatments
Find out how positive interim ADAPT trial data for CELZ-201 may signal a turning point in regenerative, non-opioid treatment approaches for chronic lower back pain.
Features & Analysis
Standard Process launches Cultivate symposium to advance whole-food nutrition strategies for healthy aging practitioners
Discover why Standard Process’ Cultivate symposium aims to close clinical education gaps in whole-food nutrition and reshape healthy aging care for practitioners.
Medical Devices & Diagnostics
Illumina’s Billion Cell Atlas marks inflection point for AI-enabled drug discovery in 2026
Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks